Supernus Pharmaceuticals Q3 Earnings Call Highlights
Supernus Pharmaceuticals reported Q3 earnings, highlighting $42M in ZURZUVAE-related revenue and a 53% increase in U.S. sales. ONAPGO sales rose 27% QoQ, and GOCOVRI reached record sales. The company raised 2026 revenue guidance to $875M-$900M and expects to complete its merger with Indivior by Nov. 2.
How this was made
The 30-second read
Why it matters
Key trading drivers are the raised 2026 revenue and non-GAAP operating earnings outlook, improved GAAP and adjusted profitability, and deal-related conditionality on guidance, plus FDA-related supply and exclusivity updates for ONAPGO.
Market read
Traders get a fresh earnings-and-guidance datapoint plus merger-close timing, which can reprice near-term expectations and increase headline sensitivity into Nov. 2.
What to watch
ONAPGO supply and enrollment run-rate assumptions, plus the timing uncertainty for SPN-817 data (2028 expected but timing update after another enrollment quarter), could drive revisions even after the raised 2026 outlook.
Background
The piece summarizes Supernus’ Q3 earnings call, covering ZURZUVAE collaboration economics, ONAPGO supply/enrollment progress and FDA exclusivity, GOCOVRI sales, and updated 2026 guidance alongside the pending Indivior merger.
Ticker impact
Supernus raised 2026 revenue guidance to $875M-$900M and lifted non-GAAP operating earnings to $160M-$180M after Q3 profitability improvement.
Likely upward pressure as traders price in higher 2026 outlook, tempered by uncertainty around Indivior merger close and integration.
The article contains fresh, company-specific guidance changes plus a conditional statement tied to the Indivior merger closing, both directly affecting valuation expectations.
Market effects
Improving profitability and raised guidance in CNS specialty pharma can modestly support sentiment toward profitable niche drugmakers and their commercial execution.
Primarily US-listed small/mid-cap pharma sentiment; limited direct regional spillover beyond healthcare equities.
Limited global read-through, though FDA exclusivity and supply approvals reinforce regulatory execution credibility for CNS therapies.
Counterpoint
The guidance is explicitly conditional on the Indivior merger closing, so the market may discount the raised numbers until deal completion and integration milestones are clearer.
Key entities
- companySupernus Pharmaceuticals
NASDAQ-listed specialty CNS pharma reporting Q3 results, raising 2026 guidance, and progressing the Indivior merger.
- companyIndivior
Counterparty in the pending merger expected to close Nov. 2, with guidance conditionality referenced by Supernus.
- productONAPGO
Supernus Parkinson’s disease therapy discussed with cleared supply/enrollment backlog and FDA orphan-drug exclusivity recognition.
- productZURZUVAE
Biogen-reported sales referenced via Supernus collaboration revenue and growth metrics.
- productGOCOVRI
Amantadine-based therapy with Q3 net sales and prescription growth and an all-time high net sales figure.
